October 7, 2019
BriaCell Therapeutics Corp. today announced that it has initiated dosing in a Phase I/IIa clinical study of its lead product...
October 2, 2019
BriaCell Therapeutics Corp. announced on August 23, 2019 that it will hold a special meeting of shareholders on October 22,...
October 1, 2019
BriaCell Therapeutics Corp. is a clinical-stage biotechnology company specializing in targeted immunotherapy for advanced breast cancer.
September 25, 2019
BriaCell Therapeutics announced the addition of immunology expert, Cara L. Haymaker, Ph.D., to its Scientific Advisory Board, effective immediately.
September 20, 2019
BriaCell is pleased to announce a non-brokered private placement of up to approximately 8,571,428 common shares in the capital of...
September 19, 2019
BriaCell Therapeutics Corp. today announces that Dr. Williams, presented clinical updates of its Phase I/IIa clinical trial of Bria-IMT™.
September 16, 2019
BriaCell Therapeutics Corp., announces that the Company will be presenting at the 2nd Annual Next Gen Immuno-Oncology Congress.